Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

about

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

Item

http://www.wikidata.org/entity/Q55016411

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

@en

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

@nl

type

Item

label

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

@en

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

@nl

prefLabel

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

@en

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

@nl

P1476

Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

@en

P2093

Charles A Kunos

http://www.w3.org/2001/XMLSchema#string

S Percy Ivy

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

Structure, function, and mechanism of ribonucleotide reductases.

Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.

Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Cisplatin induces platelet apoptosis through the ERK signaling pathway.

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.

Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein

P304

149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2018.00149

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29868473

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

5949312

http://www.w3.org/2001/XMLSchema#string